Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
At a glance
- Drugs AGN 195263 (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 28 Jun 2017 Status changed from recruiting to discontinued.
- 15 Dec 2016 Status changed from not yet recruiting to recruiting.
- 22 Nov 2016 New trial record